

## 2<sup>ND</sup> WORLD CONGRESS OF GASTROENTEROLOGY AND DIGESTIVE DISEASES



**DrC. Carmen E. Viada González<sup>1</sup>, DrC. Martha María Fors López<sup>2</sup>, DrC. Mayra Ramos Suzarte<sup>1</sup>, MCs. Lázara García Fernández<sup>1</sup>, MCs. Aliuska Frias Blanco<sup>1</sup>, DrC. Yaimarelis Saumell Nápoles<sup>1</sup>, DrC. Tania Crombet Ramos<sup>1</sup>**

*1 Center for Molecular Immunology (CIM), Havana, Cuba*

*2 University of the Americas (UDLA), Quito, Ecuador*

### Meta-analysis of clinical trials in patients with pancreatic cancer

#### Abstract:

**Background:** In Cuba, pancreatic cancer is among the top 15 cancer sites in terms of incidence and ninth in mortality. Purpose: To evaluate the efficacy and safety of nimotuzumab in the treatment of patients with pancreatic cancer. Methodology: Four clinical trials with nimotuzumab were included: one from Germany, one from China, and two from Cuba. Forest plots and funnel plots were used. All analyses were performed using RevMan 5, version 5.0. Results: The meta-analysis showed a benefit from combining nimotuzumab with chemotherapy. Overall, the addition of nimotuzumab to chemotherapy provides greater benefit than chemotherapy alone for patients with pancreatic cancer. Conclusions: The monoclonal antibody nimotuzumab is registered by our Regulatory Agency, CECMED, for pancreatic cancer, among other cancers. The mAb nimotuzumab is considered safe, as most of the reported adverse events were mild, non-serious, and have no causal relationship with the product.

**Keywords:** pancreatic cancer, meta-analysis, nimotuzumab, forest plot.

#### Biography:

B.S. in Mathematics, University of Havana, July 1991.

B.S. in Cybernetics, University of Havana, July 1995.

M.S. in Mathematics with a Minor in Statistics and Probabilities, University of Havana, 2000.

M.S. in Applied Statistics, University of Hasselt, Belgium, 2007.

Ph.D. in Mathematics, University of Havana, 2023.

Terminating Research Fellow, 2024.

Full Professor, 2024.